Based on Panel vote and the reference noted below, daratumumab/lenalidomide/dexamethasone combination was added as a category 1 option to the preferred regimen list for previously treated multiple myeloma.


See Submission for references.
multiple myeloma.

| MYEL-D, page 2 | External request: Amgen Inc. Review the information provided in order to correct a footnote that states “The dose of carfilzomib used in the ENDEAVOR trial is higher than the dose approved by the FDA.” | The Panel consensus was in support of this change, the footnote was removed from the updated guideline. | 27 | 0 | 0 | 0 |